Emergence of High-Level Gentamicin Resistance in Group G Streptococci

Faibis, F.; Fiacre, A.; Demachy, M. C.
December 2001
European Journal of Clinical Microbiology & Infectious Diseases;Dec2001, Vol. 20 Issue 12, p901
Academic Journal
The article focuses on the emergence of high level gentamicin resistance in group G streptococci (GGS). GGS appear to be commensals, but they share a number of virulence factors with A streptococci. Since there have been reports of clinical failure and potential antibiotic tolerance among betahaemolytic streptococci [1, 2], many authors recommend that combination therapy be used for synergy in the initial treatment of severe infections caused by these organisms. Consequently, the emergence of high-level resistance to gentamicin in betahaemolytic streptococci has potentially important clinical implications. Previously, high-level resistance to gentamicin in GGS had been observed in only one strain. Prior to this report, the only GGS strain demonstrating high-level resistance to gentamicin was Streptococcus dysgalactiae BM2721, which was resistant to all available aminoglycosides.


Related Articles

  • VITEK 2 and PHOENIX fail to detect high-level gentamicin-resistant Enterococcus faecium isolates with aac-aph gene. Arslan, U.; Tuncer, I.; Fındık, D.; Bozdogan, B. // Indian Journal of Medical Microbiology;Apr2011, Vol. 29 Issue 2, p198 

    The article presents a study examining the diagnostic capability of automated methods VITEK and PHOENIX systems to detece high-level gentamicin-resistant Enterococcus faecium. It notes that the study indicated that some of the strains with aac-aph gene reported as susceptible by the two methods....

  • Comparative Pharmacokinetics of Gentamicin after Intravenous, Intramuscular, Subcutaneous and Oral Administration in Broiler Chickens. E. Abu-Basha; N. Idkaidek; A. Al-Shunnaq // Veterinary Research Communications;Aug2007, Vol. 31 Issue 6, p765 

    Abstract  The pharmacokinetics and bioavailability of gentamicin sulphate (5 mg/kg body weight) were studied in 50 female broiler chickens after single intravenous (i.v.), intramuscular (i.m.), subcutaneous (s.c.) and oral administration. Blood samples were collected at time 0...

  • Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition. Claire Seaton; James Ignas; Simon Muchohi; Gilbert Kokwaro; Kathryn Maitland; Alison H. Thomson // Journal of Antimicrobial Chemotherapy (JAC);Mar2007, Vol. 59 Issue 4, p681 

    Objectives The World Health Organization recommends that all children admitted with severe malnutrition should routinely receive parenteral ampicillin and gentamicin; despite this, mortality remains high. Since this population group is at risk of altered volume of distribution, we...

  • Gentamicin and ototoxicity: why this drug is still in use. Turnidge, John D.; Waterston, John A. // Medical Journal of Australia;6/18/2012, Vol. 196 Issue 11, p665 

    The author discusses the relationship between the drug gentamicin and ototoxicity and why it is still used in 2012. According to the authors, a retrospective analysis conducted by Ahmed and colleagues found that delayed clinical detection of vestibulotoxicity and an apparent lack of a...

  • Parasite Load Decrease during Application of a Safe and Easily Applied Antileishmanial Aminoglycoside Cream. Salah, Afif Ben; Zaâtour, Amor; Ben Messaoud, Nathalie; Kidar, Abdelhamid; Smith, Philip L.; Kopydlowski, Karen M.; Kreishman-Deitrick, Mara; Nielsen, Carl J.; Novitt-Moreno, Anne; Ransom, Janet H.; Morizot, Gloria; Grogl, Max; Buffet, Pierre A. // PLoS Neglected Tropical Diseases;May2014, Vol. 8 Issue 5, p1 

    The article discusses the application of antileishmanial aminoglycoside cream to decrease the parasite load. An overview about the WR 279,396, which is a novel hydrophilic formulation of 15% paromomycin and 0.5% gentamicin, is provided. The author also talks about a trial that determines whether...

  • Gentamicin ototoxicity: a 23-year selected case series of 103 patients. Ahmed, Rebekah M.; Hannigan, Imelda P.; MacDougall, Hamish G.; Chan, Raymond C.; Halmagyi, G. Michael // Medical Journal of Australia;6/18/2012, Vol. 196 Issue 11, p701 

    The article discusses the results of a retrospective case review of patients with severe bilateral vestibular loss associated with gentamicin treatment in hospital between 1988 and 2010. The researchers aimed to determine the relationship between vestibulotoxicity and gentamin dose or dosing...

  • Narrow Versus Broad Spectrum Antibacterials: Factors in the Selection of Pneumococcal Resistance to β-Lactams. Carbon, C.; Isturiz, R. // Drugs;2002, Vol. 62 Issue 9, p1289 

    Streptococus pneumoniae represents an interesting model to discuss the relative impact of broad versus narrow spectrum antibacterials as potential selectors for resistance. Indeed, this pathogen is responsible for potentially severe infections in the community, and has a great capacity for...

  • AbaR4 replaces AbaR3 in a carbapenem-resistant Acinetobacter baumannii isolate belonging to global clone 1 from an Australian hospital. Hamidian, Mohammad; Hall, Ruth M. // Journal of Antimicrobial Chemotherapy (JAC);Nov2011, Vol. 66 Issue 11, p2484 

    Objectives To explore the diversity of genomic resistance islands in multiply antibiotic-resistant Acinetobacter baumannii isolates in global clone 1 (GC1) from Australian hospitals. Methods PCR was used to characterize isolates, detect antibiotic resistance genes and insertion sequences and...

  • Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Lim, Sue; Bast, Darrin; McGeer, Allison; Azavedo, Joyce de; Low, Donald E.; de Azavedo, Joyce // Emerging Infectious Diseases;Jul2003, Vol. 9 Issue 7, p833 

    Clinical antimicrobial susceptibility breakpoints are used to predict the clinical outcome of antimicrobial treatment. In contrast, microbiologic breakpoints are used to identify isolates that may be categorized as susceptible when applying clinical breakpoints but harbor resistance mechanisms...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics